Anti-CD123 CAR NK cells
Phase 1Cell therapy
Anti-CD123 CAR NK cells is one of 7 small molecule programs targeting AML - Acute Myeloid Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in AML - Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Rezlidhia
RRigel Pharmaceuticals
Approved
Fludara
SanofiPhase 2
Grafapex
MMedexus Pharma, Inc.
Phase 2
Venclexta
AbbViePhase 1
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
CLN-049
CCullinan Therapeutics Inc.
Phase 1
Anti-CD123 CAR NK cells
CChongqing Precision Biotech Co., Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
AML - Acute Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-CD123 CAR NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details